Johnson & Johnson (JNJ) PT Lowered to $175 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Johnson & Johnson's (JNJ) Potential to Change Multiple Myeloma Treatment Paradigm in Underappreciated, Stock Remains Top Pick - Cantor Fitzgerald
January 24, 2022 6:24 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $215.00 price target on Johnson & Johnson (NYSE: JNJ) in light of the upcoming PDUFA for the company's CAR-T therapy.
The analyst quotes: "The PDUFA date for Johnson and Johnson (JNJ) and Legend Biotech's BCMA (B-cell... More
